NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025
NanoViricides will showcase its clinical-stage nanoviricide technology targeting multiple viral diseases at the LSX World Congress, highlighting its potential to address unmet medical needs through a novel antiviral approach.
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to resist viral escape, announced it will present at the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on Wednesday, Sept. 17, at 12:30 p.m. The presentation will showcase the company's innovative nanoviricide technology platform, which represents a significant advancement in antiviral therapy development.
The company's lead drug candidate, NV-387, is a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, long COVID, influenza and other respiratory viral infections, as well as MPOX/smallpox infections. Another advanced drug candidate is NV-HHV-1 for the treatment of shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials, marking a critical milestone in its development pipeline.
NanoViricides' platform technology is based on intellectual property from TheraCour Pharma Inc., with the company holding exclusive, sub-licensable field licenses for multiple viral disease treatments. The technology involves special purpose nanomaterials that form the basis of their novel nanoviricide drug candidates. Additional information about the company's technology and development programs can be found at https://ibn.fm/uoB3n.
The company's drug development pipeline extends beyond respiratory viruses to include treatments for oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever and Ebola virus. This broad approach addresses multiple global health challenges through a single platform technology. The company holds worldwide exclusive perpetual licenses for specific targeting mechanisms in perpetuity for numerous human viral diseases.
NV-CoV-2 and NV-CoV-2-R represent the company's COVID-19 drug candidates, with the latter encapsulating remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. This strategic approach potentially accelerates regulatory pathways for certain drug candidates.
As with any pharmaceutical development, NanoViricides notes that the path to drug approval is extremely lengthy and requires substantial capital. There can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. However, the presentation at LSX World Congress 2025 provides an important platform for showcasing this innovative technology to potential partners and investors in the life sciences community.